Antikoagulation bei HIT II: Wann therapeutisch -
wann prophylaktisch?

Literatur

• 1 Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced Thrombocytopenia. New York; Marcel Dekker 2000: 43-80
• 2 Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac A M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.  Thromb Haemost. 1995;  73 21-28
• 3 Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF-4 complexes in patients with heparine-induced thrombocytopenia.  Br J Haematol. 1996;  92 954-959
• 4 Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.  Thromb Haemost. 1994;  71 247-251
• 5 Visentin G P, Ford S E, Scott J P, Aster R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.  J Clin Invest. 1994;  93 81-88
• 6 Chong B H, Pitney W R, Castaldi P A. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation.  Lancet. 1982;  2 1246-1249
• 7 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med. 1996;  101 502-507
• 8 Chong B H, Fawaz I, Chesterman C N, Berndt M C. Heparin-induced thrombocytopenia: mechanisms of interaction of the heparin-dependent antibody with platelets.  Br J Haematol. 1989;  73 502-507
• 9 Kelton J G, Smith J W, Warkentin T E, Hayward C P, Denomme G A, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.  Blood. 1994;  83 3232-3239
• 10 Cines D B, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia.  N Engl J Med. 1987;  316 581-589
• 11 Warkentin T E, Hayward C P, Boshkov L K, Santos A V, Sheppard J A, Bole A P, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparine-induced thrombocytopenia.   Blood. 1994;  84 361-369
• 12 Warkentin T E, Elavathil L J, Hayward C P, Johnston M A, Russell J I, Kelton J G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.  Am Intern Med. 1997;  127 804-812
• 13 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood. 2000;  96 846-851
• 14 Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-associated Thrombocytopenia Study (HAT) investigators.  Circulation. 1999;  100 587-593
• 15 Warkentin T E. Limitations of conventional treatment options for heparin-induced thrombocytopenia.  Semin Haematol. 1998;  35 17-25
• 16 Wallis D E, Workman D L, Lewis B E, Stehen L, Pifarre R, Moran J F. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.  Am J Med. 1999;  106 629-635
• 17 Warkentin T E, Sheppard J A, Horsewood P, Simpson P J, Moore J C, Kelton J G. Impact of the patient population on the risk for heparin-induced thrombocytopenia.  Blood. 2000;  96 (5) 1703-1708
• 18 Warkentin T E, Levine M N, Hirsh J, Horsewood P, Roberts R S, Gent M, Kelton J G. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
• 19 Aster R H. Heparin-induced thrombocytopenia and thrombosis.  N Engl J Med. 1995;  332 1374-1376
• 20 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.  Thromb Haemost. 2001;  85 950-957
• 21 Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.  Circulation. 1999;  99 73-80
• 22 Warkentin T E, Kelton J G. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: absence of an anamnestic immune response, and implications for repeat use in patients with a history of HIT.  Blood. 1998;  92 1-182a